Brian Kobilka, MD, who received the 2012 Nobel Prize in Chemistry for his studies of G protein-coupled receptors (GPCRs), shared his team’s progress in understanding receptor activation — and how that might guide drug development — at last week’s Flexner Discovery Lecture.

Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a Komen Scholar for her leadership in breast cancer research.

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.

Alpha-gal allergy has commonly been referred to as “the red meat” allergy, but doctors at the Vanderbilt Asthma, Sinus and Allergy Program (ASAP) helped uncover that not only red meat, but some medications, can contain alpha-gal.

Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

Treatment of anemia caused by chronic kidney disease or other diseases often requires repeated — and costly — injections or infusions of an artificial form of the hormone erythropoietin (EPO), which stimulates production of red blood cells.

New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.